INVESTABOT
Equity Research
XNAS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-08-14. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-07-31. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-07-20. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-07-06. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-06-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-06-03. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-06-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-05-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-05-21. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
DexCom (DXCM) had 1 Form 144 pre-sale notice filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing refer…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/12/2026 | Heller Bridgette P | — | SELL | -1,012 | $88 | $89,349 |
| 8/12/2026 | AUGUSTINOS NICHOLAS | — | GIFT | -1,075 | — | — |
| 8/3/2026 | FOLETTA MARK G | — | SELL | -2,000 | $85 | $170,640 |
| 7/31/2026 | FOLETTA MARK G | — | SELL | -2,000 | $80 | $160,000 |
| 7/20/2026 | SAYER KEVIN R | Executive Chair | SELL | -26,756 | $76 | $2,041,999 |
| 7/15/2026 | Brown Michael Jon | EVP Chief Legal Compliance Off | SELL | -1,700 | $74 | $126,514 |
| 7/6/2026 | SAYER KEVIN R | Executive Chair | SELL | -26,756 | $72 | $1,926,432 |
| 6/15/2026 | Brown Michael Jon | EVP Chief Legal Compliance Off | SELL | -1,700 | $76 | $128,435 |
| 6/15/2026 | FOLETTA MARK G | — | SELL | -3,801 | $74 | $281,651 |
| 6/15/2026 | FOLETTA MARK G | — | SELL | -199 | $75 | $14,889 |
| 6/4/2026 | Coleman Jon | EVP, Chief Commercial Officer | SELL | -4,911 | $74 | $364,052 |
| 6/3/2026 | Coleman Jon | EVP, Chief Commercial Officer | SELL | -4,912 | $73 | $358,576 |
| 5/28/2026 | Ashley Euan A. | — | GRANT | 5,565 | — | — |
| 5/28/2026 | ALTMAN STEVEN R | — | GRANT | 5,565 | — | — |
| 5/28/2026 | Malady Kyle | — | GRANT | 5,575 | — | — |
| 5/28/2026 | AUGUSTINOS NICHOLAS | — | GRANT | 5,575 | — | — |
| 5/28/2026 | FOLETTA MARK G | — | GRANT | 6,331 | — | — |
| 5/28/2026 | Heller Bridgette P | — | GRANT | 5,575 | — | — |
| 5/28/2026 | Osterloh Albert Frederick IV | — | GRANT | 1,630 | — | — |
| 5/28/2026 | Driscoll Rimma | — | GRANT | 5,605 | — | — |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 8/14/2026 | MICHAEL BROWN | — | 1,700 | SEC |
| 8/12/2026 | Heller Bridgette P | — | 1,012 | SEC |
| 8/3/2026 | FOLETTA MARK G | — | 2,000 | SEC |
| 7/31/2026 | FOLETTA MARK G | — | 2,000 | SEC |
| 7/20/2026 | KEVIN R SAYER | — | 26,756 | SEC |
| 7/15/2026 | MICHAEL BROWN | — | 1,700 | SEC |
| 7/6/2026 | KEVIN R SAYER | — | 26,756 | SEC |
| 6/15/2026 | FOLETTA MARK G | — | 4,000 | SEC |
| 6/15/2026 | MICHAEL BROWN | — | 1,700 | SEC |
| 6/4/2026 | JON C COLEMAN | — | 4,911 | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 99,324,365 | $3,977,499,286 | — | 8/13/2024 |
| Vanguard Group | 49,074,378 | $3,257,066,468 | — | 1/29/2026 |
| BlackRock | 130,943,377 | $2,728,498,664 | — | 2/12/2026 |
| BlackRock | 181,839,137 | $2,709,644,964 | 18.5% | 8/7/2026 |
| BlackRock | 153,459,371 | $2,552,412,396 | 17.2% | 5/13/2026 |
| State Street | 50,705,806 | $1,268,029,579 | 13.8% | 8/7/2026 |
| State Street | 44,718,554 | $1,225,353,183 | — | 2/13/2026 |
| State Street | 44,559,847 | $1,150,868,223 | -0.3% | 5/15/2026 |
| JP Morgan Chase | 25,882,101 | $442,059,883 | — | 2/11/2026 |
| JP Morgan Chase | 27,476,470 | $397,812,270 | 6.2% | 5/13/2026 |
| Morgan Stanley | 7,131,282 | $349,117,531 | 7.8% | 8/13/2026 |
| Morgan Stanley | 6,722,646 | $338,188,909 | — | 5/27/2026 |
| Morgan Stanley | 6,617,044 | $318,091,043 | -1.6% | 5/15/2026 |
| Goldman Sachs | 4,107,916 | $276,668,171 | 12.1% | 8/14/2026 |
| DE Shaw | 4,145,568 | $275,141,348 | — | 2/17/2026 |
| Citadel Advisors | 92,904,567 | $270,129,299 | 131.2% | 8/14/2026 |
| JP Morgan Chase | 27,765,095 | $255,541,310 | 1.1% | 8/12/2026 |
| Goldman Sachs | 3,767,447 | $250,045,485 | — | 3/25/2026 |
| Goldman Sachs | 3,666,035 | $230,227,021 | -2.7% | 5/15/2026 |
| AQR Capital | 3,237,720 | $218,060,428 | 49.0% | 8/14/2026 |